Author + information
- Received July 16, 1984
- Revision received October 8, 1984
- Accepted October 25, 1984
- Published online March 1, 1985.
- Glenn J.R. Whitman, MD*,1,2,
- Britton Chance, PhD1,
- Hans Bode, MD1,
- John Maris, BS1,
- John Haselgrove, PhD1,
- Richard Kelley, MD1,
- Bernard J. Clark, MD1 and
- Alden H. Harken, MD, FACC1
- ↵*Address for reprints: Glenn J. R. Whitman, MD, c/o Alden H. Harken, MD, Department of Surgery, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, Colorado 80262.
An 8 month old girl presented with undiagnosed non-anatomic congenital cardiomyopathy with massive car-diomegaly on chest X-ray film. Her older sibling had died suddenly at 6 months of age from what appeared to be a similar abnormality. Utilizing phosphorus-31 nuclear magnetic resonance (P-31 NMR) surface coil spectroscopy, a metabolic disorder was demonstrated in both her myocardium and skeletal muscle, revealing a phos-phocreatine (PCr) to inorganic phosphate (Pi) ratio of half of that for a normal control infant. Manipulation of serum substrate availability indicated that medium chain triglycerides alone did not improve myocardial metabolism, but that intravenous glucose or oral carbohydrate loading raised the myocardial PCr/Piratio from 1.0 ± 0.05 to 1.8 ± 0.1 (p < 0.01) without significantly affecting the PCr/Pivalue of her resting skeletal muscle.
This study demonstrates the feasibility of using P-31 nuclear magnetic resonance to evaluate the biochemistry of the human myocardium in vivo and to diagnose a metabolic abnormality. Phosphorus-31 nuclear magnetic resonance can thus be used to optimize therapy for human disease.
- Received July 16, 1984.
- Revision received October 8, 1984.
- Accepted October 25, 1984.
- American College of Cardiology Foundation